Back to Search Start Over

Bone metastases are measurable: the role of whole-body MRI and positron emission tomography

Authors :
Oprea-Lager, Daniela
Cysouw, Matthijs C.
Boellard, Ronald
Deroose, Christophe M.
De Geus-Oei, Lioe-Fee
Lopci, Egesta
Bidaut, Luc
Herrman, Ken
Fournier, Laure S.
Bauerle, Tobias
DeSouza, Nandita M.
Lecouvet, Frederic
Oprea-Lager, Daniela
Cysouw, Matthijs C.
Boellard, Ronald
Deroose, Christophe M.
De Geus-Oei, Lioe-Fee
Lopci, Egesta
Bidaut, Luc
Herrman, Ken
Fournier, Laure S.
Bauerle, Tobias
DeSouza, Nandita M.
Lecouvet, Frederic

Abstract

Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is regarded unsuitable for response assessment of bone metastases and in the current Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1) guideline bone metastases are deemed unmeasurable. Nevertheless, the advent of functional and molecular imaging modalities such as whole-body magnetic resonance imaging (WB-MRI) and positron-emission tomography (PET) has improved the ability for follow-up of bone metastases, regardless of their morphology. Both these modalities not only have improved sensitivity for visual detection of bone lesions, but also allow for objective measurements of bone lesion characteristics. WB-MRI provides a global assessment of skeletal metastases and for a one-step “all-organ” approach of metastatic disease. Novel MRI techniques include diffusion-weighted imaging (DWI) targeting highly cellular lesions, dynamic contrast-enhanced MRI (DCE-MRI) for quantitative assessment of bone lesion vascularization, and multiparametric MRI (mpMRI) combining anatomical and functional sequences. Recommendations for a homogenization of MRI image acquisitions and generalizable response criteria have been developed. For PET, many metabolic and molecular radiotracers are available, some targeting tumor characteristics not confined to cancer type (e.g. 18F-FDG) while other targeted radiotracers target specific molecular characteristics, such as prostate specific membrane antigen (PSMA) ligands for prostate cancer. Supporting data on quantitative PET analysis regarding repeatability, reproducibility, and harmonization of PET/CT system performance is available. Bone metastases detected on PET and MRI can be quantitatively assessed using validated methodologies, both on a

Details

Database :
OAIster
Notes :
application/pdf, Oprea-Lager, Daniela, Cysouw, Matthijs C., Boellard, Ronald, Deroose, Christophe M., De Geus-Oei, Lioe-Fee, Lopci, Egesta, Bidaut, Luc, Herrman, Ken, Fournier, Laure S., Bauerle, Tobias, DeSouza, Nandita M. and Lecouvet, Frederic (2021) Bone metastases are measurable: the role of whole-body MRI and positron emission tomography. Frontiers in Oncology, 11 . p. 4948. ISSN 2234-943X, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1306192047
Document Type :
Electronic Resource